We are a clinical-stage, fully-integrated, pharmaceutical company committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases.
Our product pipeline consists of both small-molecule targeted therapies and large-molecule immunotherapies for the treatment of cancer and autoimmune diseases. We intend to build a diverse portfolio of innovative products through internal development, licensing, and strategic partnerships to increase our likelihood of success, diversify our longer-term revenue stream and deliver on our promise the bring innovative treatments to patients worldwide.
Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. Its investors include Eli Lilly & Co., a Fortune 500 company and one of the most globalized and innovative pharmaceutical companies in the world. As a leading biomedical venture fund in China, Lilly Asia Ventures provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.
Founded in 2006, Qiming is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou and Hong Kong. In 2016, Qiming raised a US healthcare fund, and set up Qiming US office in Seattle. Currently Qiming manages five US Dollar funds and four RMB funds with US$2.7 billion assets under management.